Latest Period
n/a
Security Snapshot
Chemomab Therapeutics Ltd. - Ordinary Shares / American Depositary Shares (CMMB) Institutional Ownership
CUSIP: 16385C104
13F Institutional Holders and Ownership History from Q1 2021 to Q3 2025
Institutions Reporting
Shares (Excl. Options)
Price
$0.89
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Ordinary Shares / American Depositary Shares
- Symbol
- CMMB on Nasdaq
- Shares outstanding
- 412,914,375
- SEC-reported price per share
- $0.89
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- CMMB - Chemomab Therapeutics Ltd. - Ordinary Shares / American Depositary Shares is tracked under CUSIP 16385C104.
- Latest finished 13F holder period is not available.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 14 to 0 between Q2 2025 and Q3 2025.
- SEC-reported value moved from $4,907,708 to $0.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Schedule 13D/G
Open SEC evidence
Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.
Security key
16385C104
Latest holder period
n/a
13F holders
13D/G owners
3
CIK / CUSIP context first
CMMB full holder history
Chemomab Therapeutics Ltd. SEC filings
Chemomab Therapeutics Ltd. company facts
Chemomab Therapeutics Ltd. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 16385C104:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
3
Security
CMMB
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| MORGAN STANLEY | 3.2% | -65% | $15,327,382 | -$22,120,527 | 13,213,260 | -59% | Morgan Stanley | 31 Jul 2025 |
| OrbiMed Israel BioFund GP Limited Partnership | 4.8% | $1,328,636 | 969,807 | ORBIMED ISRAEL BIOFUND GP LIMITED PARTNERSHIP | 18 Jun 2025 | |||
| SPHERA FUNDS MANAGEMENT LTD. | 4.8% | $1,152,548 | 900,428 | Sphera Funds Management Ltd. | 31 Mar 2025 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
19
Latest
n/a
Rows shown
1-19 of 19
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | 0 | $0 | -$4,891,584 | $0.89 | 0 |
| 2025 Q2 | 4,230,788 | $4,907,708 | +$580,031 | $1.16 | 14 |
| 2025 Q1 | 3,731,679 | $4,067,948 | -$471,792 | $1.09 | 17 |
| 2024 Q4 | 4,160,723 | $7,530,756 | -$700,297 | $1.81 | 16 |
| 2024 Q3 | 4,549,767 | $7,142,810 | +$3,023,403 | $1.57 | 15 |
| 2024 Q2 | 2,672,756 | $2,441,306 | +$15,800 | $0.91 | 15 |
| 2024 Q1 | 2,661,598 | $2,073,381 | -$89,384 | $0.78 | 14 |
| 2023 Q4 | 2,813,782 | $1,434,861 | +$143,796 | $0.51 | 16 |
| 2023 Q3 | 2,530,576 | $2,264,861 | -$524 | $0.90 | 11 |
| 2023 Q2 | 2,531,115 | $3,327,272 | -$562,185 | $1.32 | 10 |
| 2023 Q1 | 2,889,758 | $4,560,246 | -$695,559 | $1.59 | 12 |
| 2022 Q4 | 3,313,486 | $10,603,060 | +$239,615 | $3.20 | 13 |
| 2022 Q3 | 3,249,704 | $8,092,000 | -$130,379 | $2.49 | 13 |
| 2022 Q2 | 3,288,318 | $12,166,000 | -$114,849 | $3.70 | 13 |
| 2022 Q1 | 3,307,612 | $15,880,000 | -$99,757 | $4.79 | 15 |
| 2021 Q4 | 3,288,041 | $22,686,000 | +$310,558 | $6.90 | 14 |
| 2021 Q3 | 3,241,493 | $35,915,000 | +$733,108 | $11.08 | 13 |
| 2021 Q2 | 3,085,723 | $58,690,000 | +$1,761,108 | $19.02 | 11 |
| 2021 Q1 | 2,876,992 | $82,600,000 | +$82,600,000 | $28.74 | 10 |